Intrasense (ALINS) - Total Liabilities
Based on the latest financial reports, Intrasense (ALINS) has total liabilities worth €14.45 Million EUR (≈ $16.89 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Intrasense - Total Liabilities Trend (2008–2025)
This chart illustrates how Intrasense's total liabilities have evolved over time, based on quarterly financial data. See ALINS current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Intrasense Competitors by Total Liabilities
The table below lists competitors of Intrasense ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Acrinova AB
ST:ACRI-A
|
Sweden | Skr453.97 Million |
|
Investsmart Group Ltd
AU:INV
|
Australia | AU$6.41 Million |
|
Copaur Minerals Inc
V:CPAU
|
Canada | CA$182.98K |
|
Andalan Sakti Primaindo PT
JK:ASPI
|
Indonesia | Rp30.76 Billion |
|
Celsius Resources Limited
F:FX8
|
Germany | €1.07 Million |
|
Asuransi Jasa Tania Tbk
JK:ASJT
|
Indonesia | Rp255.97 Billion |
|
Park Ha Biological Technology Co., Ltd.
NASDAQ:PHH
|
USA | $1.58 Million |
|
Way 2 Vat Ltd
AU:W2V
|
Australia | AU$7.17 Million |
Liability Composition Analysis (2008–2025)
This chart breaks down Intrasense's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ALINS stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.26 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.81 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Intrasense's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Intrasense (2008–2025)
The table below shows the annual total liabilities of Intrasense from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €14.45 Million ≈ $16.89 Million |
+139.65% |
| 2024-12-31 | €6.03 Million ≈ $7.05 Million |
+90.52% |
| 2023-12-31 | €3.17 Million ≈ $3.70 Million |
-29.62% |
| 2022-12-31 | €4.50 Million ≈ $5.26 Million |
+18.87% |
| 2021-12-31 | €3.78 Million ≈ $4.42 Million |
-10.10% |
| 2020-12-31 | €4.21 Million ≈ $4.92 Million |
+15.83% |
| 2019-12-31 | €3.63 Million ≈ $4.25 Million |
+62.78% |
| 2018-12-31 | €2.23 Million ≈ $2.61 Million |
-3.94% |
| 2017-12-31 | €2.32 Million ≈ $2.72 Million |
-23.55% |
| 2016-12-31 | €3.04 Million ≈ $3.55 Million |
-22.58% |
| 2015-12-31 | €3.93 Million ≈ $4.59 Million |
+5.42% |
| 2014-12-31 | €3.72 Million ≈ $4.35 Million |
-9.28% |
| 2013-12-31 | €4.11 Million ≈ $4.80 Million |
+1.47% |
| 2012-12-31 | €4.05 Million ≈ $4.73 Million |
-33.73% |
| 2011-12-31 | €6.11 Million ≈ $7.14 Million |
+85.71% |
| 2010-12-31 | €3.29 Million ≈ $3.84 Million |
+210.42% |
| 2009-12-31 | €1.06 Million ≈ $1.24 Million |
+22.00% |
| 2008-12-31 | €868.00K ≈ $1.01 Million |
-- |
About Intrasense
Intrasense S.A. designs and develops software solution for advanced visualization and analysis of multimodality medical images under the Myrian name worldwide. It offers the Myriad platform, a visualization solution that provides a suite of clinical tools and artificial intelligence algorithms for prostate, lung, and brain pathologies; and the Liflow solution, an oncological imaging platform that… Read more